Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) --  Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies, today announced the appointment of Jennifer Fox as its Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., Ph. D as Head of Research and Development and Chief Medical Officer.

“We are thrilled to welcome Tanya and Jen to our executive team,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “Tanya is a deeply experienced physician-scientist leader and Jen is a seasoned healthcare finance and corporate development leader. With their decades of industry leadership experience, they will each be an invaluable addition to Zenas as we head into our next phase of growth, advancing multiple global programs in late-stage clinical development with a goal to deliver differentiated I&I directed therapies to patients in need around the world.”

Ms. Fox is an experienced finance and corporate development executive with an extensive track record in corporate finance and healthcare investment banking, advising numerous private and public companies with respect to strategy, financings and mergers and acquisitions. Prior to joining Zenas, Ms. Fox served as Chief Financial Officer at Nuvation Bio, a publicly traded biotechnology company. She previously served as a Managing Director and Co-Head of North America Healthcare Corporate and Investment Banking Group at CitiGroup. Prior to CitiGroup, Ms. Fox held senior positions in investment banking at Deutsche Bank, Bear Stearns, Bank of America and Prudential Securities. She holds B.S. degrees in finance and marketing from Manhattan College.

Dr. Fischer is a physician-scientist with deep experience in academia and at both pharmaceutical and biotechnology companies, leading early and late-stage research and development programs across multiple therapeutic areas, including neurology and rare diseases. Prior to joining Zenas, she served as Chief Development Officer and Head of Translational Medicine at Biohaven, a publicly traded biopharmaceutical company. Dr. Fischer began her industry career at Bristol Myers Squibb and held R&D leadership roles of increasing responsibility at EMD-Serono, Sanofi-Genzyme and Alnylam. She is a neurologist and held appointments at Yale University School of Medicine following the completion of her Neurology residency at Yale New Haven Hospital. She obtained MD and PhD degrees from the University of Medicine and Dentistry of New Jersey - Robert Wood Johnson Medical School and Rutgers University, respectively, and was awarded the prestigious Presidential Early Career Award for Scientists and Engineers (PECASE).

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies for patients in need around the world. With clinical development capabilities and operations globally, Zenas is advancing a portfolio of potentially differentiated autoimmune therapeutics in areas of high unmet medical need. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, bifunctional, non-cytolytic, humanized monoclonal antibody that mimics the action of antigen-antibody complexes by binding CD19 and FcγRIIb to inhibit B-lineage cell activity. In several early-stage clinical studies, including in various autoimmune diseases, 198 subjects were treated with obexelimab. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc. Obexelimab is currently being studied in a global Phase 3 clinical study in patients with IgG4 Related Disease and a global Phase2/3 study in patients with warm autoimmune hemolytic anemia (wAIHA). Clinical development of obexelimab for Multiple Sclerosis and Systemic Lupus Erythematosus is under evaluation.

More information on the Phase 3 (INDIGO) study for the treatment of IgG4 Related Disease is available at clinicaltrials.gov: NCT05662241. More information on the Phase 3 (SApHiAre) study for the treatment of wAIHA is available at clinicaltrials.gov: NCT05786573.


Investor and Media Contact: Joe Farmer, President & COO Zenas BioPharma IR@zenasbio.com  


Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

THỦ THUẬT HAY

Cách tạo ảnh trang Facebook trong suốt trên smartphone

Gần đây, phong trào tạo ảnh với trang facebook trong suốt đang được chia sẻ rất nhiều trong cộng đồng mạng. Bài viết hôm nay, chúng tôi sẽ hướng dẫn các bạn thực hiện rất đơn giản trên smartphone.

Hướng dẫn theo dõi và cảnh báo dung lượng 3G/4G sử dụng

Trên hệ điều hành iOS thì Apple cũng đã cung cấp một công cụ giúp bạn theo dõi dung lượng 3G/4G đã sử dụng. Tuy nhiên không có tính năng cảnh báo cho người dùng khi vượt quá dung lượng sử dụng.

Cách ghi âm trên máy tính đơn giản nhưng không phải ai cũng biết

Không cần máy ghi âm, không cần điện thoại, bạn hoàn toàn có thể ghi âm bằng chính chiếc máy tính mình đang sử dụng. Tuy nhiên, rất ít bạn biết cách ghi âm trên máy tính. Vì vậy, ngay trong bài viết này mình sẽ hướng

ProtonVPN - dịch vụ VPN miễn phí cho phép bạn mã hóa kết nối Internet

Một phần mềm VPN tiện dụng khi bạn cần duyệt web mà không để lại dấu vết hoặc duyệt các nội dung hạn chế mà không gặp bất kì rào cản nào - đó là ProtonVPN. Đây là một ứng dụng VPN đơn giản nhưng cực kì an toàn. Hãy

Nên chọn smartphone dùng chip Intel hay Qualcomm?

Thị trường chip xử lý ngày càng sối động, trong khi Qualcomm lâu đời thì Intel cũng không kém cạnh, vậy chip Intel hay Qualcomm cái nào tốt hơn cho smartphone.

ĐÁNH GIÁ NHANH

Đánh giá pin Meizu MX6: Viên pin 3.060 mAh cho kết quả sử dụng quá bất ngờ

Với 3.060 mAh, liệu Meizu MX6 có đủ để đáp ứng nhu cầu sử dụng của người dùng? Hãy cùng tìm lời giải đáp cho câu hỏi trên ngay trong bài viết này.

Lenovo Yoga Slim 7i Carbon: đẹp mỹ mãn trong từng đường nét

Lenovo Yoga Slim 7i Carbon vừa được giới thiệu vào ngày 12/10 dành cho đối tượng khách hàng cao cấp. Chiếc laptop siêu mỏng nhẹ này có bề ngoài đẹp không tì vết cùng sức mạnh đáng gờm bên trong.

Đánh giá Samsung Galaxy S20 FE 5G: món quà dành cho người hâm mộ của Samsung

Samsung Galaxy S20 FE 5G là chiếc điện thoại Samsung thứ tư trong dòng S được phát hành trong năm nay. Ngoại trừ hai thiết bị Note 20, đây có thể cho là phiên bản giá rẻ nổi bật nhất trong vô số các mẫu điện thoại dòng